EU drugs agency admits that it misses UK data and expertiseBMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1488 (Published 10 June 2021) Cite this as: BMJ 2021;373:n1488
- Rory Watson
Alexis Goosdeel, director of the European Monitoring Centre for Drugs and Drug Addiction, has admitted that Brexit has affected the work of the Lisbon based agency.
Introducing the centre’s annual report on 9 June,1 Goosdeel explained that the UK’s departure from the European Union was depriving his team of valuable British expertise and data for the centre, which provides policy makers with scientific, evidence based, and comparable information of the evolving drug problem.
“This is a very painful point for us,” he said. “Because of Brexit, we have lost a broad range of excellent and fantastic experts and colleagues, including the …